Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism

Objective: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). We evaluated whether MPC inhibitors (MPCi) might correct impairments in branched chain amino acid (BCAA) catabolism, whic...

Full description

Bibliographic Details

Published in:	Molecular Metabolism
Main Authors:	Daniel Ferguson, Sophie J. Eichler, Nicole K.H. Yiew, Jerry R. Colca, Kevin Cho, Gary J. Patti, Trevor M. Shew, Andrew J. Lutkewitte, Sandip Mukherjee, Kyle S. McCommis, Natalie M. Niemi, Brian N. Finck
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Subjects:	Pyruvate Liver Branched chain amino acids Mitochondria Diabetes
Online Access:	http://www.sciencedirect.com/science/article/pii/S2212877823000285